Cemiplimab

Cemiplimab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	PD-1
Clinical data
Synonyms	REGN-2810
ATC code	None
Identifiers
CAS Number	1801342-60-8
ChemSpider	none
UNII	6QVL057INT
Chemical and physical data
Formula	C₆₃₈₀H₉₈₀₈N₁₆₈₈O₂₀₀₀S₄₄
Molar mass	143.6 g/mol

Cemiplimab (REGN-2810) is a monoclonal antibody under development as a drug for the treatment of squamous cell skin cancer,^[1] myeloma,^[2] and lung cancer.^[3]

In Sept 2018 it was approved by the US FDA for treating "patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation". ^[4] cemiplimab-rwlc will be marketed as Libtayo.^[4]

Mechanism

It targets PD-1 so it acts as a checkpoint inhibitor.^[5]

References

↑ H. Spreitzer (2 January 2018). "Neue Wirkstoffe: Cemiplimab". Österreichische Apothekerzeitung (in German) (1/2018).
↑ Clinical trial number NCT03194867 for "Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients" at ClinicalTrials.gov
↑ Clinical trial number NCT03430063 for "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer" at ClinicalTrials.gov
1 2 FDA approves first treatment for advanced form of the second most common skin cancer 28 Sept 2018
↑ New PD-1 Inhibitor OK'd for Cutaneous SCC - Sixth PD-1/PD-L1 checkpoint inhibitor approved by agency 2018

Monoclonal antibodies for the immune system

Immune system ("-l(i[m])-")

Human ("-limu-")	Immunosuppression: Abrilumab Adalimumab Anifrolumab^† Atorolimumab Avelumab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab^† Fresolimumab Gimsilumab Golimumab Ianalumab^† Lanadelumab Lenzilumab Lerdelimumab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Otilimab Oxelumab§ Pamrevlumab Placulumab Relatlimab^† Sarilumab Sifalimumab Tabalumab Tezepelumab^† Ulocuplumab Varlilumab Immune activation: Ipilimumab Atezolizumab Durvalumab Nivolumab Pembrolizumab Tremelimumab^† Urelumab Other: Bertilimumab Zanolimumab
Mouse ("-limo-")	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric ("-lixi-")	Andecaliximab^† Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized ("-lizu-")	Immunosuppressive: Aselizumab Apolizumab^§ Benralizumab Camrelizumab^† Cedelizumab Certolizumab pegol Crizanlizumab^† Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab^† Fontolizumab Inebilizumab^† Itolizumab Lampalizumab^† Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140^† Quilizumab Ravulizumab^† Reslizumab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab^† Siplizumab Spartalizumab^† Talizumab Teplizumab Tibulizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412^§ Non-immunosuppressive: Ibalizumab
Chimeric + humanized ("-lixizu-")	Otelixizumab Sutimlimab^† Tavolimab
Veterinary ("-lvet-")	Gilvetmab

Interleukin ("-k(i[n])-")

Human ("-kinu-")	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab^† Ustekinumab
Humanized ("-kizu-", "-kinzu-")	Anrukinzumab Bimekizumab^† Clazakizumab Enokizumab Gevokizumab Ixekizumab Mirikizumab^† Lebrikizumab Olokizumab^† Perakizumab Risankizumab^† Tildrakizumab
Veterinary ("-kivet-")	Lokivetmab

Inflammatory lesions ("-les-")

Mouse ("-leso-")	Besilesomab Fanolesomab^‡ Lemalesomab Sulesomab

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.